All News

Convention1.jpg

EULAR 2023: Featured Industry Presentations

d Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
cush.tkr_.jpg

Colchicine and the Risk of Knee and Hip Replacement

d Jack Cush, MD

Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Belimumab in Lupus Nephritis

d Jack Cush, MD

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Read Article
brain,pain,perception,cns

Orbitofrontal Cortex Implants to Assess Chronic Pain

d Jack Cush, MD

Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling. 

Read Article
A full house for the #EULAR2023 Opening session @eular_org setting the tone for an exciting few days to come! @RheumNow https://t.co/bZSIL78mU6
Aurelie Najm AurelieRheumo ( View Tweet)
Tuesday Night Rheumatology: POD 4: Rheumatoid Arthritis: Decisive Therapeutics https://t.co/GzLE2XLe1q

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: A Family History of Ankylosing Spondylitis https://t.co/3U7DG8P52c https://t.co/lxial62ujS

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Evaluation of Sacroiliac Joint RheumNow Live: Prof. Denis Poddubnyy, Charité University Hospital, Berlin https://t.co/vH866d5sy6 https://t.co/zSMMBedyoG

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevalence of PsA, Spondyloarthritis and Rheumatoid Arthritis in Norway Recent reports have suggested a rising and unrecognized number of patients with PsA and axSpA compared to RA. This has implications on diagnosis and population care. https://t.co/D0SvKP2MIa https://t.co/Gjh0oSZ5S2

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Landmark Study to Accelerate Personalized Lupus Treatments The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE. https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH

Links:

Dr. John Cush RheumNow ( View Tweet)
Tonight! The final Tuesday Night Rheumatology of May. This webinar will feature highlights from these lectures followed by live audience Q & A: Methotrexate Use: 50 Yr. Perspective Myths vs Reality in RA Biosimilars - Back on the Agenda https://t.co/NRAtlQ96e3 https://t.co/j6WVyFacUc

Links:

Dr. John Cush RheumNow ( View Tweet)
TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T

Links:

Dr. John Cush RheumNow ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review proves Keystones 60%/40%/20% response rule in biologic-naive #RA. 21 RCTs 1999-2017; For bio-naïve pts the ACR20/50/70 was 61.4%/37.8%/ 18.8%. For Bio-IR it was 48.5%/27.3%/12.9%- roughly 10pts lower. https://t.co/Xr3QEw278J https://t.co/OAfNghXlvB

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR

Links:

Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF

Links:

Dr. John Cush RheumNow ( View Tweet)
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E

Links:

Dr. John Cush RheumNow ( View Tweet)
A claims cohort comparison of #RA pts with H.zoster (n 1 866 ) and pts without HZ (38,846). RA+/HZ+ pts had significantly greater Hospitalizations, emergency visits (esp <30d post HZ Dx; adj IRR hosp=3.4; ED=3.7) and higher Total HC costs https://t.co/89GLUK93dO https://t.co/9jweduoBHw

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May. This webinar will feature highlights from these lectures followed by live audience Q & A: Methotrexate Use: 50 Yr. Perspective Myths vs Reality in RA Biosimilars - Back on the Agenda https://t.co/0OenWkXarV https://t.co/yUHwslkZ9o

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×